TheEdgeResearch
Home / Stocks / MTRY

Monterey Bio Acquisition Corporation (MTRY)

NASDAQ Financial Services Shell Companies
$11.14 ▼ -0.27%
Market Cap
$48.3M
Sector
Financial Services
Industry
Shell Companies
Beta
0.00
52-Wk Range
10.21-12.0
CEO
Murat Omur
Country
US
Currency
USD

Monterey Bio Acquisition Corporation operates in the Shell Companies industry of the Financial Services sector, headquartered in New York City, NY, US. The stock last traded at $11.14, down 0.27% on the session, giving a market capitalisation of $48.3M. On trailing twelve-month figures it carries a trailing P/E of -25.32, a net margin of 0.0%. Its beta of 0.00 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-25.32
Price / Sales
0.00
Price / Book
1.62
EV / EBITDA
-23.62
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.00
Current ratio
0.23
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
—
IPO date
2021-11-22
Headquarters
New York City, NY, US
About Monterey Bio Acquisition Corporation

Monterey Bio Acquisition Corporation currently lacks substantial operational activities. Its primary goal is to achieve a business combination—including but not limited to mergers, capital stock exchanges, asset acquisitions, or reorganizations—with companies in the biotechnology industry. The firm, established in 2020, was formerly known as Chardan FinTech Acquisition Corp. and rebranded to Monterey Bio Acquisition Corporation in April 2021. It is headquartered in New York, New York.

Comparable companies

Monterey Bio Acquisition Corporation is most often compared with the following Financial Services names:

ACABGRDIGTIHOLOPRSRROCLVSACZEO
More research on MTRY
MTRY technical analysis MTRY TheEdge Score Compare against peers
Open full interactive analysis & DCF →